Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grassley Seeks FDA, CMS Clarification On Drug Compounding

This article was originally published in The Pink Sheet Daily

Executive Summary

In a letter to both agencies, Grassley asks FDA to what extent the federal government should assume oversight of drug compounding.

You may also be interested in...



FDA Cracks Down On Three Pharmacies Compounding Inhalation Drugs

In warning letters to the pharmacies, FDA says their compounding of mass amounts of drugs goes “well beyond” traditional compounding.

FDA Cracks Down On Three Pharmacies Compounding Inhalation Drugs

In warning letters to the pharmacies, FDA says their compounding of mass amounts of drugs goes “well beyond” traditional compounding.

Large-Scale Compounding Operations May Be A “Loophole” For Counterfeits, Slobodin Says

The House Energy & Commerce counsel says that some compounding operations now resemble manufacturing facilities rather than pharmacies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel